SAN DIEGO, Feb. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
Participants can access the live conference call by dialing 888-632-3382 (US) or 785-424-1677 (International) using the conference ID NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.
If you are unable to attend the webcast and would like further information on this announcement, please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-839-6136 (US) or 402-220-2572 (International) using the conference ID NBIX. The call will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals in diseases with high unmet medical needs through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and INGREZZA, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine plans to commercialize INGREZZA in the United States upon approval by the FDA.
Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-2016-results-300402890.html
SOURCE Neurocrine Biosciences, Inc.
Subscribe to our Free Newsletters!